NCT01469260 Pedometer Use to Prevent Excessive Pregnancy Weight Gain in Overweight Women Status TERMINATED Phase NA
NCT01466764 Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain Status TERMINATED Phase NA
NCT01466751 Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits Status COMPLETED Phase NA
NCT01463423 Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Status COMPLETED Phase NA
NCT01461473 Comparative Outcomes Management With Electronic Data Technology (COMET) Study Status COMPLETED Phase NA
NCT01460641 Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer Status COMPLETED Phase N/A
NCT01454843 LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser Status COMPLETED Phase PHASE4
NCT01454687 Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes Status WITHDRAWN Phase NA
NCT01451476 Human Skin Aging: Clinical Parameters and Gene Expression Profiling Status COMPLETED Phase N/A
NCT01450683 Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Status TERMINATED Phase PHASE2
NCT01449279 Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy Status COMPLETED Phase PHASE2
NCT01443819 Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy Status TERMINATED Phase PHASE3
NCT01442714 Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS Status TERMINATED Phase PHASE2
NCT01437449 Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Status COMPLETED Phase PHASE2
NCT01425762 Influence of Patient Choice of Intrathecal Morphine on Post-cesarean Delivery Pain. Status COMPLETED Phase NA
NCT01423201 Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk Status COMPLETED Phase N/A
NCT01421719 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Status COMPLETED Phase PHASE4